ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,127.79
1.26%
US Tech 100
17,446.00
2.17%
다우존스 지수
38,675.68
1.18%
Bitcoin
64,003.66
1.77%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Affimed NV (AFMD)

  7. Affimed NV (AFMD) 뉴스

AFMD

Affimed NV (AFMD)

Affimed NV
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:AFMD
일자시간출처헤드라인심볼기업
2024/04/2417:05GlobeNewswire Inc.Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical OncologyNASDAQ:AFMDAffimed NV
2024/03/2819:30GlobeNewswire Inc.Affimed Reports 2023 Financial Results and Operational ProgressNASDAQ:AFMDAffimed NV
2024/03/2119:30GlobeNewswire Inc.Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024NASDAQ:AFMDAffimed NV
2024/03/1205:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
2024/03/0620:34Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
2024/03/0620:30GlobeNewswire Inc.Affimed Announces 1-for-10 Reverse Stock SplitNASDAQ:AFMDAffimed NV
2024/01/0906:45Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
2024/01/0906:05GlobeNewswire Inc.Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung CancerNASDAQ:AFMDAffimed NV
2024/01/0822:11Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
2024/01/0822:00GlobeNewswire Inc.Affimed Announces Leadership Change and Organizational RestructuringNASDAQ:AFMDAffimed NV
2024/01/0320:30GlobeNewswire Inc.Affimed Announces Sale of Wholly-Owned Subsidiary AbCheckNASDAQ:AFMDAffimed NV
2023/12/1120:10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
2023/12/1120:02GlobeNewswire Inc.Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer PatientsNASDAQ:AFMDAffimed NV
2023/12/1120:00GlobeNewswire Inc.Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)NASDAQ:AFMDAffimed NV
2023/12/0420:30GlobeNewswire Inc.Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24NASDAQ:AFMDAffimed NV
2023/11/3021:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
2023/11/1420:30GlobeNewswire Inc.Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational ProgressNASDAQ:AFMDAffimed NV
2023/11/0920:30GlobeNewswire Inc.Affimed Announces Acimtamig as International Nonproprietary Name for AFM13NASDAQ:AFMDAffimed NV
2023/11/0720:30GlobeNewswire Inc.Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023NASDAQ:AFMDAffimed NV
2023/11/0401:05GlobeNewswire Inc.Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of CancerNASDAQ:AFMDAffimed NV
2023/11/0222:05GlobeNewswire Inc.Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual MeetingNASDAQ:AFMDAffimed NV
2023/11/0119:30GlobeNewswire Inc.Affimed to Participate in Upcoming Investor ConferencesNASDAQ:AFMDAffimed NV
2023/10/0419:40Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
2023/10/0419:30GlobeNewswire Inc.Affimed Announces Listing Transfer to Nasdaq Capital MarketsNASDAQ:AFMDAffimed NV
2023/09/2722:05GlobeNewswire Inc.Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of CancerNASDAQ:AFMDAffimed NV
2023/09/2119:30GlobeNewswire Inc.Affimed to Present at the Cantor Global Healthcare Conference 2023NASDAQ:AFMDAffimed NV
2023/09/1219:30GlobeNewswire Inc.Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK® for the Treatment of Patients with Relapsed or Refractory Hodgkin LymphomaNASDAQ:AFMDAffimed NV
2023/09/0719:30GlobeNewswire Inc.Affimed to Present at the H.C. Wainwright Annual Global Investment ConferenceNASDAQ:AFMDAffimed NV
2023/08/2218:00GlobeNewswire Inc.Affimed Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal DevelopabilityNASDAQ:AFMDAffimed NV
2023/08/1019:45Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
 검색 관련기사 보기:NASDAQ:AFMD

최근 히스토리

CCOM
SILVER
SILVER
NYSE
XOM
Exxon Mobil
NASDAQ
GOOGL
Alphabet
PM
XAUUSD
Gold vs US Dollar
NYSE
JPM
JP Morgan Chase
NASDAQ
AMZN
Amazon.com
USOTC
BASFY
BASF (QX)
NASDAQ
MSFT
Microsoft
FX
USDEUR
US Dollar vs Euro
NASDAQ
NVDA
NVIDIA
USOTC
RHHBY
Roche (QX)
AMEX
XLF
Financial Select Sector
COIN
ETHUSD
Ethereum
NYSE
KO
Coca Cola
NYSE
DIS
Walt Disney
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유